GLP ‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study
Authors' conclusion
In France, GLP-1RA use among psychotropic users remained primarily in T2DM, regardless of psychotropic class. Off-label use for psychotropic-induced weight gain appeared very limited. High persistence rates were notable, given the challenges of treatment adherence in mental health populations. These findings suggested a predominantly persistent use of GLP-1RAs within labelled indications in the psychiatric population.
Study context
- Population
- Prevalent users of psychotropic medications who initiated GLP-1RAs between 2017 and 2023 in Francepatients initiating GLP-1RAs after psychotropic use
- Participants
- 102,709 users
- Outcome
- Indication for GLP-1RA
Methodological detailsgroup-based trajectory modelling, French National Health Data System
- Group-based trajectory modelling
- French National Health Data System
Main finding
As reported in the abstract
Identified with T2DM
95%
Lacked a clear indication for GLP-1RA
Less than 5%
Observational data: associations, not effects.
Further findings
Most frequently dispensed psychotropics
- Anxiolytics/hypnotics
- > 66%
- Antidepressants
- > 56%
- Antipsychotics
- > 15%
Trajectories of monthly GLP-1RA dispensings · 1 year
- Predominant trajectory: high persistence with GLP-1RA treatment over 1 year
- > 60%
- Early disruption trajectory: proportion of T2DM (lowest)
- 80%
- Early disruption trajectory: use of antiemetic drugs (highest)
- 8%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →